HARBARTH S, MONNET D, ALBRICH W; Interscience Conference on Antimicrobial Agents and Chemotherapy (43rd: 2003: Chicago, Ill.).

Abstr Intersci Conf Antimicrob Agents Chemother Intersci Conf Antimicrob Agents Chemother. 2003 Sep 14-17; 43: abstract no. K-1406.

Geneva Univ. Hosp., Geneva, Switzerland.

BACKGROUND: Ecologic analyses allow measurement of the individual and group-level effect of antibiotic (AB) exposure on antibiotic resistance (ABR). Our aim was to correlate outpatient AB use with ABR in S. pneumoniae and S. pyogenes in Europe, North America and Australia. METHODS: Data from ABR surveillance networks were systematically reviewed. Proportions of penicillin-non-susceptible S. pneumoniae (PNSP), macrolide-resistant S. pneumoniae (MRSP) and macrolide-resistant S. pyogenes (MRGAS) were calculated for 20 countries and linked to national AB sales data. Correlations between AB consumption and ABR were calculated using Spearman coefficients. RESULTS: Volume and pattern of AB use and prevalence of ABR varied greatly across countries. Total AB use varied from 9.0 DDD/1,000 pop/day in The Netherlands to 36.5 DDD/1,000 pop/day in France. Macrolide use varied from 1.0 (Sweden) to 6.0 DDD/1,000 pop/day (France). Rates of ABR were low in Scandinavia and Netherlands, medium level in Central Europe, UK and Australia, and high in South Europe, France and USA. Total AB consumption was correlated with PNSP (r=0.75; p<0.001), as were macrolide use with MRSP (r=0.88; p<.001) and MRGAS (r=0.71; p=0.004). [table: see text] CONCLUSIONS: National prevalence of PNSP, MRSP and MRGAS is directly correlated with antibiotic selection pressure in 20 developed countries.

Publication Types:

• Meeting Abstracts

Keywords:

• Anti-Bacterial Agents
• Australia
• Drug Resistance
• Europe
• France
• Netherlands
• North America
• Penicillins
• Scandinavia
• Sweden
• utilization

Other ID:

• GWAIDS0025862

UI: 102265486

From Meeting Abstracts